MedMira Receives Investigational Testing Authorization for its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test

Stock Information for MedMira Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About MedMira Inc.

MedMira Reports FY2025 Fourth Quarter and Year End Financial Results
Health Canada Approves MedMira's Reveal(R) Rapid TP Test - Urgent New Tool In The Battle Against Syphilis
MedMira Announces Launch of Clinical Trial for Its Multiplo(R) TP/HIV Self-Test in Canada
MedMira Reports Second Quarter Results FY2025
MedMira Inc. and Lovell Announce Partnership to Increase Access to Reveal(R) G4 HIV-1/2 rapid test for VA, Department of Defense
MedMira Reports Second Quarter Results FY2025
MedMira Announces Partnership with MediGroup Physician Services in the United States
MedMira Announces Exclusive Distribution Agreement with Trimedic Inc. for Canada

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.